Uptake and Effectiveness of FOLFIRINOX for Advanced Pancreatic Cancer: a Population-based Study. Issue 1 (January 2018)

• Record Type: Journal Article
• Authors: Karim, S.; Zhang-Salomans, J.; Biagi, J.J.; Asmis, T.; Booth, C.M.
• Is Part Of: Clinical oncology. Volume 30:Issue 1(2018)
• Page Start: e16
• Page End: e21
• Publication Date: 2018-01
• Subjects: Chemotherapy -- FOLFORINOX -- metastatic -- pancreatic cancer; Oncology -- Periodicals; Tumors -- Periodicals; Cancer -- Treatment -- Periodicals; Radiotherapy -- Periodicals; Neoplasms -- Periodicals; Cancer -- Radiotherapy; Cancer -- Treatment; Oncology; Medical radiology; Radiotherapy; Tumors; Electronic journals; Periodicals; 616.994
• DOI: 10.1016/j.clon.2017.10.017
• Languages: English
• ISSNs: 0936-6555

Abstract

Abstract: Aims: Although FOLFIRINOX is a standard treatment option for advanced pancreas cancer, there are few data describing utilisation and effectiveness in routine clinical practice. Here we report practice patterns and outcomes in the general population of Ontario, Canada. Materials and methods: Using the Ontario Cancer Registry and New Drug Funding Program, we identified all patients with pancreas cancer treated with palliative intent gemcitabine or FOLFIRINOX in Ontario during 2006–2014. FOLFIRINOX became available in Ontario's single-payer health system in November 2011. Gemcitabine cases were classified as pre-FOLFIRINOX era (2006–2010) or post-FOLFIRINOX era (2011–2014). Cases treated with perioperative chemotherapy were excluded. Comparisons of proportions between study groups were made using the chi-square test. Overall survival was measured from the date of chemotherapy initiation. Results: During 2006–2014, 3826 patients in Ontario were treated with gemcitabine ( n = 3042) or FOLFIRINOX ( n = 784) chemotherapy for advanced pancreas cancer. Uptake of FOLFIRINOX increased from 41% (206/505) of treated cases in 2012 to 56% (274/486) of treated cases in 2014. The median overall survival of patients treated with gemcitabine was 5.0 months in 2006–2010 and 4.8 months in 2011–2014. The median overall survival of FOLFIRINOX patients treated in 2011–2014 was 8.2 months. Conclusion: The use of FOLFIRINOX in the general population has increased since 2011. Survival outcomes show a substantial efficacy–effectiveness gap between the pivotal Prodige 4/ACCORD 11 clinical trial and routine practice. Highlights: Limited data describe utilization and outcomes of FOLFIRINOX for advanced pancreatic cancer in routine practice. We describe chemotherapy delivery for all patients with advanced pancreas cancer in Ontario during 2006–2014. Uptake of FOLFIRINOX increased significantly between 2011 and 2014. The median overall survival with FOLFIRINOX was 8.2 months (compared to 11.1 months in the pivotal RCT). Outcomes show a substantial efficacy-effectiveness gap between the pivotal RCT and routine practice.